rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    TARS
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Tarsus Pharmaceuticals CEO Bobak Azamian sells $803,100 in shares
      Nov 18Investing.comTARS
      Tarsus Pharmaceuticals director William Link sells $979,744 in stock
      Nov 12Investing.comTARS
      Is Raised Revenue Outlook Altering The Investment Case For Tarsus Pharmaceuticals (TARS)?
      Nov 6Yahoo FinanceTARS
      Is Tarsus Pharmaceuticals (TARS) Below Fair Value On Cash Flow?
      Nov 6Yahoo FinanceTARS
      Tarsus Pharmaceuticals (TARS) Could Be 31% Undervalued Following Record Q3 Sales
      Nov 5Yahoo FinanceTARS
      Tarsus to Participate in Upcoming Investor Conferences
      Nov 5Yahoo FinanceTARS
      Tarsus Pharmaceuticals Inc (TARS) (Q3 2026) Earnings Call Highlights: Record Xtendi Sales and ...

      Tarsus Pharmaceuticals Inc (TARS) posted record Q3 2026 Xtendi net product sales of $194.6 million, up nearly 64% year over year, and lifted its full-year 2026 guidance to $715-$730 million.

      Nov 5Yahoo FinanceTARS
      Tarsus Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary
      Nov 4Yahoo FinanceTARS
      Tarsus Pharmaceuticals stock price target raised to $106 by H.C. Wainwright
      Nov 4Investing.comTARS
      Tarsus Pharmaceuticals Q3 Earnings Call Highlights
      Nov 4Yahoo FinanceTARS
      Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Tops Revenue Estimates

      Tarsus Pharmaceuticals (TARS) delivered earnings and revenue surprises of +45.46% and +3.06%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

      Nov 3Yahoo FinanceTARS
      Tarsus Pharmaceuticals Q3 2026 Earnings Call Transcript
      Nov 3BenzingaTARS
      How Much Upside is Left in Tarsus Pharmaceuticals (TARS)? Wall Street Analysts Think 30.78%

      The average of price targets set by Wall Street analysts indicates a potential upside of 30.8% in Tarsus Pharmaceuticals (TARS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

      Nov 2Yahoo FinanceTARS
      Earnings To Watch: Tarsus Pharmaceuticals Inc (TARS) Q3 2026 -- GF Value Sees 196% Upside
      Nov 2Yahoo FinanceTARS
      My 'Eye' Is On Tarsus Pharmaceuticals (NASDAQ:TARS)

      Tarsus Pharmaceuticals may be undervalued after its pullback, with Xdemvy growth, pipeline upside, and key catalysts ahead. Read the full analysis here on TARS stock.

      Nov 1Seeking AlphaTARS
      Tarsus Pharmaceuticals Appoints Neera Clase as Chief Commercial Officer
      Oct 28Yahoo FinanceTARS
      Earnings Preview: Tarsus Pharmaceuticals, Inc. (TARS) Q3 Earnings Expected to Decline
      Oct 27Yahoo FinanceTARS
      ETFs Are Net Sellers of Tarsus Pharmaceuticals (TARS) on Oct. 16
      Oct 20Yahoo FinanceTARS
      Analysts Are Bullish on These Healthcare Stocks: Merck & Company (MRK), Tarsus Pharmaceuticals (TARS)

      Detailed price information for Merck & Company (MRK-N) from The Globe and Mail including charting and trades.

      Oct 13The Globe and MailTARSMRK
      Bank of America Securities Reaffirms Their Buy Rating on Tarsus Pharmaceuticals (TARS)

      Detailed price information for Tarsus Pharmaceuticals Inc (TARS-Q) from The Globe and Mail including charting and trades.

      Oct 13The Globe and MailTARS
      Tarsus Pharmaceuticals: XDEMVY Now Pays The Bills, And The Retina Deals Work Like Options
      Oct 6Seeking AlphaTARS
      Analysts Have Conflicting Sentiments on These Healthcare Companies: TransMedics Group (TMDX), Regeneron (REGN) and Tarsus Pharmaceuticals (TARS)

      Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

      Oct 3The Globe and MailTARSTMDX
      Tarsus Pharmaceuticals (TARS) Receives a Buy from Goldman Sachs

      Detailed price information for Tarsus Pharmaceuticals Inc (TARS-Q) from The Globe and Mail including charting and trades.

      Sep 25The Globe and MailTARS
      Goldman Sachs initiates Tarsus Pharmaceuticals stock coverage with buy rating
      Sep 24Investing.comTARS
      Tarsus Pharmaceuticals Insider Sold Shares Worth $979,744, According to a Recent SEC Filing
      Sep 17Yahoo FinanceTARS
      Tarsus Pharmaceuticals Insider Sold Shares Worth $1,220,885, According to a Recent SEC Filing

      Elizabeth Yeu Lin, Chief Medical Officer, on September 04, 2026, sold 13,953 shares in Tarsus Pharma

      Sep 9Yahoo FinanceTARS
      Tarsus Pharmaceuticals Insider Sold Shares Worth $387,940, According to a Recent SEC Filing

      Seshadri Neervannan, Chief Operating Officer, on September 04, 2026, sold 4,564 shares in Tarsus Pha

      Sep 9Yahoo FinanceTARS
      Jefferies raises Tarsus Pharmaceuticals price target on guidance
      Sep 8Investing.comTARS
      Tarsus Pharmaceuticals stock hits all-time high at 85.29 USD
      Sep 4Investing.comTARS
      Update: Tarsus Pharmaceuticals Shares Rise After Closing Alkeus Pharmaceuticals Acquisition
      Sep 4Yahoo FinanceTARS
      Tarsus Pharmaceuticals Closes Acquisition of Alkeus Pharmaceuticals

      Tarsus Pharmaceuticals (TARS) said Friday that it has completed its acquisition of retinal disease-f

      Sep 4Yahoo FinanceTARS
      Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care
      Sep 4Yahoo FinanceTARS
      Tarsus to Participate in Upcoming Investor Conferences

      IRVINE, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to attend ...

      Sep 1Business InsiderTARS

      This is the newest page. Registered accounts read further back.